Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist